This group of proven professionals has collectively brought to market more than 200 pharmaceutical products, including some of the largest blockbusters in the world. "The team possesses a remarkable depth and range of strategic and practical expertise that is unmatched by any other consulting service available today," said a Patheon statement. The Certified Consultants roster includes:
- Leah Appel – 20 years of development experience at Bend Research and INTERx. Co-inventor of more than 35 drug delivery patents and applications.
- Brett Berner – 30 years of product development experience at Depomed, Cygnus and Ciba. Ten marketed products and 30 drug delivery patents.
- Lynn Van Campen – 30 years of development experience at Pfizer, Boehringer Ingelheim, Inhale/Nektar and the University of Wisconsin. Contributed to 18 marketed products.
- Joe Fix – 30 years of development experience at CyDex, NanoSystems/Elan, Yamanouchi and Alza. Contributed to 24 patents including four NECs, 13 LCMs, four OTCs and three generics.
- Larry Gatlin – 25 years of experience, including Genentech, Glaxo and Pfizer. Multiple patents, INDs and NDAs, more than 20 publications.
- John Kent – 30 years of development experience at Theravance, Syntex and Allergan. More than 20 products and CMC, IND and NDA filings.
- Bob Lipper – 30 years of product development experience at Pfizer and BMS. Ushered multiple products through the R&D process.
- Doug Mendenhall – 35 years of experience at Abbott, Glaxo/GSK and Merck. Contributed to 70 commercial products.
- George Mooney – 30 years of development experience at Boehringer Ingelheim, Lederle and Pfizer. One-hundred NME INDs, 15 NCEs, NDAs and more than 30 products.
- Ann Newman – 20 years of experience at BMS and SSCI/Aptuit. Contributed to eight commercial products.
- Rodney Pearlman – 30 years of development experience at Lilly, Genentech and Valentis. Chief executive officer of two start-ups, Saegis and Nuon.
- Mark Staples – 27 years of experience with early and mid-stage companies. Contributed to the launch of three products, both biologic and small molecule.



